Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;8(10):1189-98.
doi: 10.14202/vetworld.2015.1189-1198. Epub 2015 Oct 15.

Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine

Ehab El-Sayed Ibrahim  1 , Wael Mossad Gamal  1 , Amr Ismail Hassan  1 , Safy El-Din Mahdy  1 , Akram Zakria Hegazy  1 , Magdy Mahmoud Abdel-Atty  1
Affiliations

Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine

Ehab El-Sayed Ibrahim et al. Vet World. 2015 Oct.

Abstract

Aim: A comparison study was conducted to explore the best internationally available adjuvant that could be used in production of a highly potent foot and mouth disease (FMD) vaccine, that could stimulate a strong immune response and possibly give greater protection against FMD.

Materials and methods: Four experimental batches of trivalent FMD vaccine were prepared with different available oil adjuvants which included Montanide ISA 201, 206, 61 and 50.

Results: The results indicated that vaccines emulsified using Montanide ISA 201 and Montanide ISA 206 adjuvants elicited a protective humoral immune response from the 2(nd) week postvaccination (WPV) as for ISA 201 with serum neutralization test (SNT) and enzyme-linked immune sorbent assay (ELISA) antibody titers of 1.62±0.047(a) and 1.8±0.049(a), 1.59±0.076(a) and 1.836±0.077(a), and 1.71±0.06(b) and 1.96±0.074(b) for serotypes O, A, SAT2, respectively, and for ISA 206 at SNT and ELISA antibody titers of 1.5±0.082(a) and 1.84±0.084(a), 1.56±0.037(a) and 1.818±0.052(a), and 1.5±0.106(a,b) and 1.81±0.104(a,b) for FMD virus serotypes O, A and SAT2, respectively. For ISA 61 and ISA 50, the protective antibody titer appeared in the 3(rd) WPV. In the ISA 61 FMD vaccine, SNT and ELISA titer were 1.59±0.076(a) and 1.9±0.094(a), 1.53±0.056(a) and 1.83±0.070(a), and 1.5±0.082(a) and 1.84±0.094(a) for serotypes O, A and SAT2, respectively, and in the case of ISA 50 FMD vaccine, the SNT, and ELISA titer were recorded for serotypes O, A and SAT2 respectively, 1.59±0.037(a) and 1.8±0.030(a), 1.68±0.056(a,b) and 1.916±0.065(a,b), and 1.65±0.082(a) and 1.9±0.09(a). On estimating the cellular immune response, the highest delta optical density levels for ISA 201 (0.395-0.460) and ISA 206 (0.375-0.428) were observed on 14 and 21 days post vaccination (DPV) respectively, while the highest levels of lymphoproliferation for ISA 61 (0.375-0.455) and ISA 50 (0.411-0.430) were on 21 and 28 DPV, respectively.

Conclusion: The duration of immunity from Montanide ISA oils (201, 206, 61 and 50) FMD vaccines is a long-lived immunity which ranged between 32 and 38 weeks post vaccination but the Montanide ISA 201 FMD vaccine is superior to the others in the rapid cellular immune response of the vaccinated animals which showed its highest level within 14 days post vaccination.

Keywords: ELISA; FMD Montanide ISA vaccines; SNT; cellular immunity.

PubMed Disclaimer

Figures

Figure-1
Figure-1
Classification of experimental cattle.
Figure-2
Figure-2
Tracing of antibody titer against foot and mouth disease virus type (O) in different oil vaccines estimated by serum neutralization test.
Figure-3
Figure-3
Tracing of antibody titer against foot and mouth disease virus type (O) in different oil vaccines estimated by enzyme-linked immune sorbent assay.
Figure-4
Figure-4
Tracing of antibody titer against foot and mouth disease virus type (A) in different oil vaccines estimated by serum neutralization test.
Figure-5
Figure-5
Tracing of antibody titer against foot and mouth disease virus (A) in different oil vaccines estimated by enzyme-linked immune sorbent assay.
Figure-6
Figure-6
Tracing of antibody titer against foot and mouth disease virus type (SAT2) in different oil vaccines estimated by serum neutralization test.
Figure-7
Figure-7
Tracing of antibody titer against foot and mouth disease virus type (SAT2) in different oil vaccines estimated by enzyme-linked immune sorbent assay.
See this image and copyright information in PMC

References

    1. Depa P.M., Dimri U., Sharma M.C., Tiwari R. Update on epidemiology and control of foot and mouth disease –A menace to international trade and global animal enterprise. Vet. World. 2012;5(11):694–704.
    1. Longjam N., Deb R., Sarmah A.K., Tayo T., Awachat V.B., Saxena V.K. A brief review on diagnosis of foot and- mouth disease of livestock: Conventional to molecular tools. Vet. Med. Int. 2011. 2011:905768. - PMC - PubMed
    1. Rodriguez L.L., Grubman M.J. Foot and mouth disease virus vaccines. Vaccine. 2009;27(Suppl 4):D90–4. - PubMed
    1. Daoud H.M., Ibrahim E.E., El-Din W.M.G., Hassanin A.I.H. Preparation of foot and mouth disease trivalent vaccine type A O, SAT2 and determination of the Guinea pig protective dose 50 (GPPD50) Vet. World. 2013;6(11):844–851.
    1. Ibrahim E.E. Advanced studies on Foot and Mouth Disease Vaccines of sheep in Egypt. Ph.D.Sc. Thesis (Infectious Diseases) Egypt: Faculty of Veterinary Medicine, Cairo University; 2011.

LinkOut - more resources